• SAW Instruments

  Participated · Equity · Feb 2011

  SAW Instrument GmbH develops, manufactures and sells label-free biomolecular interaction analytical systems for the life sciences market. The company currently sells its systems to leading research institutions in Germany and Switzerland. Led by Managing Directors Sabine Bois and Dr. Markus Perpeet, SAW Instrument plans to expand its sales and marketing activities and extend its product portfolio. It intends to grow its market presence in Central Europe and begin initial steps into the U.S. market. The company will launch two new products, the sam5 pro and the samX, in the second and third quarters of 2011. SAW Instrument closed a second financing round to support these expansion and product plans. SAW Instruments develops, produces and distributes biosensor-based analysis systems for the life science market, with applications in medical, pharmaceutical, diagnostics and biotechnology research. Its SAW-based, marker-free detection technology can identify a wide variety of substances and analyze their physical mechanisms with high precision. The company has already sold its biosensors to leading research facilities in Germany and Switzerland. SAW Instruments received an undisclosed amount of equity funding from High‑Tech Gründerfonds and KI Kapital. The investment is intended to enable commercialization of the systems to the research market. Investors highlighted the technology’s advantages versus competing marker-free detection products and the prospect of expanding into numerous other markets.

No current team members are available.